Meeting
2018 ASCO Annual Meeting
Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
Authors
Bhavana Bhatnagar
The Ohio State Univ Comp Cancer Ctr, Columbus, OH
Bhavana Bhatnagar , Alison R. Walker , Alice S. Mims , Sumithira Vasu , Rebecca B. Klisovic , Gregory Behbehani , James Stewart Blachly , Karilyn T.M. Larkin , Meixiao Long , Qiuhong Zhao , Parvathi Ranganathan , John C. Byrd , William G. Blum , Ramiro Garzon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02299518
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7048)
DOI
10.1200/JCO.2018.36.15_suppl.7048
Abstract #
7048
Poster Bd #
108
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.
First Author: Daniel J. DeAngelo
Poster
2019 ASCO Annual Meeting
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
First Author: Daniel J. DeAngelo
Poster
2015 ASCO Annual Meeting
Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
First Author: David Shao Peng Tan
Poster
2024 ASCO Annual Meeting
An Indian real-world experience of intravenous fosnetupitant-palonosetron (IV NEPA) in preventing delayed and extended delayed CINV.
First Author: Hanmant V. Barkate